Elevated serum creatinine levels associated with fenofibrate therapy

American Journal of Health-System Pharmacy

Volumn 65, Issue 2, 2008, Pages 138-141

  McQuade, Charles R ^a   Griego, Jennifer ^a   Anderson, Joe ^a   Pai, Amy Barton ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Antilipemic agents; Blood levels; Creatinine; Dosage; Fenofibrate; Glomerular filtration rate; Hypertriglyceridemia; Kidney diseases; Kidney failure; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; CLONIDINE; CREATININE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; FUROSEMIDE; HYDRALAZINE; INSULIN GLARGINE; INSULIN LISPRO; NICOTINIC ACID; PANTOPRAZOLE; PIOGLITAZONE; QUININE SULFATE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERTRIGLYCERIDEMIA; KIDNEY DYSFUNCTION; MALE; NARANJO SCALE; NEPHROLOGY; PATIENT REFERRAL; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; VASCULAR ACCESS;

EID: 38349018842     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070005     Document Type: Article

References (20)

1. TriCor (fenofibrate tablets) package insert. North Chicago, IL: Abbott Laboratories; 2004 Nov.
2. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998; 81:7B-12B.
3. Assmann G, Schulte H, Funke H et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998; 19(suppl M):M8-14.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-97.
5. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998; 32(5, suppl 3):S142-56.
6. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. Am J Kidney Dis. 2003; 41(4, suppl 3):I-IV,S1-91.
7. Breeders N, Knoop C, Antoine M et al. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent? Nephrol Dial Transplant. 2000; 15:1993-9.
8. Lipscombe J, Lewis GF, Cattran D et al. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001; 55:39-44.
9. Ritter JL, Nabulsi S. Fenofibrate-induced elevation in serum creatinine. Pharmacotherapy. 2001; 21:1145-9.
10. Tsimihodimos V, Kakafika A, Elisaf M. Fibrate treatment can increase serum creatinine levels. Nephrol Dial Transplant. 2001; 16:1301. Letter.
11. Gajdos M, Dzurik R. Fibrates and renal function. Clin Nephrol. 2003; 60:65-6. Letter.
12. Hottelart C, El Esper N, Rose F et al. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002; 92:536-41.
13. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366:1849-61.
14. Wilson TW, Alonso-Galicia M, Roman RJ. Effects of lipid-lowering agents in the Dahl salt-sensitive rat. Hypertension. 1998; 31:225-31.
15. Wilson MW, Lay LT, Chow CK et al. Altered hepatic eicosanoid concentrations in rats treated with peroxisome proliferators ciprofibrate and perfluorodecanoic acid. Arch Toxicol. 1995; 69:491-7.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2, suppl):S1-266.
17. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30:239-45.
18. Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999; 354:219-20.
19. Dierkes J, Westphal S, Luley C. The effects of fibrates and other lipid lowering agents on plasma homocysteine levels. Expert Opin Drug Safety. 2004; 3:101-11.
20. Milionis HJ, Papakostas J, Kakafika A et al. Comparative effects of atorvastatin, simvastatin and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia. J Clin Pharmacol. 2003; 43:825-30.